The use of single-agent sorafenib in the treatment of advanced hepatocellular carcinoma patients with underlying Child-Pugh B liver cirrhosis: a retrospective analysis of efficacy, safety, and survival benefits.
about
Role of sorafenib in the treatment of advanced hepatocellular carcinoma: An updateHepatocellular carcinoma: Will novel targeted drugs really impact the next future?Clinical trials of combined molecular targeted therapy and locoregional therapy in hepatocellular carcinoma: past, present, and futureCancer and liver cirrhosis: implications on prognosis and managementSelection and management of hepatocellular carcinoma patients with sorafenib: recommendations and opinions from an Italian liver unit.Multidisciplinary management of hepatocellular carcinoma in clinical practice.GALNT14 genotype, α-fetoprotein and therapeutic side effects predict post-chemotherapy survival in patients with advanced hepatocellular carcinoma.Safety and efficacy of sorafenib in patients with advanced hepatocellular carcinoma and Child-Pugh A or B cirrhosis.Hong Kong consensus recommendations on the management of hepatocellular carcinoma.Sorafenib With and Without Transarterial Chemoembolization for Advanced Hepatocellular Carcinoma With Main Portal Vein Tumor Thrombosis: A Retrospective Analysis.Predictors of survival in patients with established cirrhosis and hepatocellular carcinoma treated with sorafenib.The clinical management of hepatocellular carcinoma in the United States, Europe, and Asia: a comprehensive and evidence-based comparison and review.The role of targeted therapy for gastrointestinal tumors.Chemotherapy for hepatocellular carcinoma: The present and the future.Sorafenib treatment in Child-Pugh A and B patients with advanced hepatocellular carcinoma: safety, efficacy and prognostic factors.FGF19/FGFR4 signaling contributes to the resistance of hepatocellular carcinoma to sorafenib.Clinical parameters predictive of outcomes in sorafenib-treated patients with advanced hepatocellular carcinoma.Combinations of single nucleotide polymorphisms WWOX-rs13338697, GALNT14-rs9679162 and rs6025211 effectively stratify outcomes of chemotherapy in advanced hepatocellular carcinoma.Adoption of Sorafenib for the Treatment of Advanced-Stage Hepatocellular Carcinoma in Oncology Practices in the United States.Implications of FGF19 on sorafenib-mediated nitric oxide production in hepatocellular carcinoma cells - a short report.Worse outcome of sorafenib therapy associated with ascites and Child-Pugh score in advanced hepatocellular carcinoma.Prognosis of patients with hepatocellular carcinoma treated with sorafenib: a comparison of five models in a large Canadian database.Metronomic capecitabine vs. best supportive care in Child-Pugh B hepatocellular carcinoma: a proof of concept.Role of monocyte-to-lymphocyte ratio in predicting sorafenib response in patients with advanced hepatocellular carcinoma
P2860
Q24619987-EA802B0D-823A-43FE-AE68-416CF741C989Q26741201-69F8C128-C959-47DF-BC7F-014BF475A2CAQ27013055-5D0EB062-4FFB-4CC7-9B25-A52776C4032DQ28068579-9288BD2F-3C19-45B6-9E1D-C608DA69A6F3Q30486078-464A992C-1C4B-45B5-8B0C-409B3639416FQ33666679-74475534-D21C-4910-8ADC-4CCE687BC3F6Q33733830-3A64950E-0F87-4581-B742-81A2B2DA40C9Q35167764-E2C4D19A-1287-480B-AEEF-D6EF93833CFEQ35631295-7182244F-B2B0-45A2-942D-B8602D99DF0FQ36371605-E8CF2AB6-8817-4A16-BEB5-635A247E4CBFQ37578600-F22F6FD5-0959-48AB-A42E-2252846DFE6AQ38217657-E29AC7C9-E4EC-418A-AA69-9F913CBEE8ADQ38222585-5196B287-FB52-44C1-B735-D4651908F459Q38639762-17D8362B-2351-499C-ABDE-1DD9794BCAC5Q39019421-FCF21FD0-9A39-491A-8095-C354120EC869Q41108851-1EE3A12F-6A0A-45E8-A476-1743CE4FAF89Q45275265-24F2DBBD-1B5F-4D2A-8B02-EB70E268A4BFQ45999534-D97892CE-5C6B-4184-A39A-EDCDCB678692Q47194525-87093940-0C57-4E62-8AF8-0725F4704F9EQ52428984-DA17DC74-B70A-4F50-9719-739593C63B78Q53324924-9B691CDB-8ED2-430E-9F08-E4EE51D34EB5Q53818658-CC26B017-1BBE-4C75-B490-F0CBF5E99DEEQ55646454-B63F8298-4FEA-401B-9A1F-8448DE70242BQ57816332-265891E5-3284-4C6E-A029-4801B3917908
P2860
The use of single-agent sorafenib in the treatment of advanced hepatocellular carcinoma patients with underlying Child-Pugh B liver cirrhosis: a retrospective analysis of efficacy, safety, and survival benefits.
description
2012 nî lūn-bûn
@nan
2012 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
The use of single-agent sorafe ...... safety, and survival benefits.
@ast
The use of single-agent sorafe ...... safety, and survival benefits.
@en
type
label
The use of single-agent sorafe ...... safety, and survival benefits.
@ast
The use of single-agent sorafe ...... safety, and survival benefits.
@en
prefLabel
The use of single-agent sorafe ...... safety, and survival benefits.
@ast
The use of single-agent sorafe ...... safety, and survival benefits.
@en
P2093
P2860
P356
P1433
P1476
The use of single-agent sorafe ...... safety, and survival benefits.
@en
P2093
Albert C Chan
Ashley Wong
Hilda Wong
Joanne Chiu
Pierre Chan
Roberta Pang
Roland Leung
Ronnie Poon
Sheung-Tat Fan
Tan To Cheung
P2860
P304
P356
10.1002/CNCR.27543
P407
P50
P577
2012-04-19T00:00:00Z